Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed May 3, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2010-04-29$7.00/sh−12,691$88,837→ 869,754 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.